# Lakefront Biotherapeutics NV: financial statements, quarterly

LKFT · Nasdaq · CIK 1421876 · [Healthcare](/sectors/healthcare.md)

Pages: [Overview](/companies/lkft.md) · [Financials](/companies/lkft/financials.md) · [Filings](/companies/lkft/filings.md) · [Insiders](/companies/lkft/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lkft/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2014-12-31) | period not labelled (2015-12-31) | period not labelled (2016-12-31) | FY2017 (2017-12-31) | FY2018 (2018-12-31) | FY2019 (2019-12-31) | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | [241](/filings/0001558370-18-002364.md) | [321](/filings/0001558370-19-002655.md) | [657](/filings/0001558370-20-003270.md) | not reported | [808](/filings/0001558370-22-004270.md) | [97.3](/filings/0001558370-23-004448.md) | [34.5](/filings/0001558370-24-004242.md) | [40.3](/filings/0001558370-25-003806.md) | [40.0](/filings/0001104659-26-035163.md) |
| Current assets | $m | not reported | [374](/filings/0001558370-18-002364.md) | [1,007](/filings/0001558370-19-002655.md) | [1,198](/filings/0001558370-20-003270.md) | [1,329](/filings/0001554855-21-000053.md) | [5,866](/filings/0001558370-22-004270.md) | [5,369](/filings/0001558370-23-004448.md) | [4,862](/filings/0001558370-23-004448.md) | [4,237](/filings/0001558370-24-004242.md) | [3,862](/filings/0001558370-25-003806.md) | [3,339](/filings/0001104659-26-035163.md) | [3,079](/filings/0001104659-26-035163.md) |
| Total assets | $m | not reported | [443](/filings/0001558370-18-002364.md) | [1,083](/filings/0001558370-19-002655.md) | [1,286](/filings/0001558370-20-003270.md) | [1,439](/filings/0001554855-21-000053.md) | [6,069](/filings/0001558370-22-004270.md) | [5,718](/filings/0001558370-23-004448.md) | [5,193](/filings/0001558370-23-004448.md) | [4,734](/filings/0001558370-24-004242.md) | [4,357](/filings/0001558370-25-003806.md) | [4,136](/filings/0001104659-26-035163.md) | [3,407](/filings/0001104659-26-035163.md) |
| Current liabilities | $m | not reported | [72.4](/filings/0001558370-18-002364.md) | [104](/filings/0001558370-19-002655.md) | [172](/filings/0001558370-20-003270.md) | [220](/filings/0001554855-21-000053.md) | [572](/filings/0001558370-22-004270.md) | [635](/filings/0001558370-23-004448.md) | [566](/filings/0001558370-23-004448.md) | [523](/filings/0001558370-24-004242.md) | [428](/filings/0001558370-25-003806.md) | [335](/filings/0001104659-26-035163.md) | [153](/filings/0001104659-26-035163.md) |
| Total liabilities | $m | not reported | [77.5](/filings/0001558370-18-002364.md) | [325](/filings/0001558370-19-002655.md) | [274](/filings/0001558370-20-003270.md) | [225](/filings/0001554855-21-000053.md) | [3,193](/filings/0001558370-22-004270.md) | [3,047](/filings/0001558370-23-004448.md) | [2,550](/filings/0001558370-23-004448.md) | [2,208](/filings/0001558370-24-004242.md) | [1,562](/filings/0001558370-25-003806.md) | [1,239](/filings/0001104659-26-035163.md) | [171](/filings/0001104659-26-035163.md) |
| Shareholders' equity | $m | [206](/filings/0001558370-18-002364.md) | [365](/filings/0001558370-19-002655.md) | [759](/filings/0001558370-20-003270.md) | [1,012](/filings/0001554855-21-000053.md) | [1,214](/filings/0001558370-22-004270.md) | [2,876](/filings/0001558370-23-004448.md) | [2,670](/filings/0001558370-24-004242.md) | [2,643](/filings/0001558370-25-003806.md) | [2,526](/filings/0001104659-26-035163.md) | [2,796](/filings/0001104659-26-035163.md) | [2,897](/filings/0001104659-26-035163.md) | [3,236](/filings/0001104659-26-035163.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Total liabilities: ifrs-full:Liabilities
- Shareholders' equity: ifrs-full:Equity

Shares outstanding: 65,897,071 at 2025-12-31, from the cover of the [20-F filed 2026-03-26](/filings/0001104659-26-035163.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.